Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial f… Read more
Bellerophon Therapeutics Inc (BLPH) - Net Assets
Latest net assets as of September 2023: $3.72 Million USD
Based on the latest financial reports, Bellerophon Therapeutics Inc (BLPH) has net assets worth $3.72 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.98 Million) and total liabilities ($1.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.72 Million |
| % of Total Assets | 74.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -34.28% |
| 10-Year Change | N/A |
| Growth Volatility | 355.82 |
Bellerophon Therapeutics Inc - Net Assets Trend (2012–2022)
This chart illustrates how Bellerophon Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bellerophon Therapeutics Inc (2012–2022)
The table below shows the annual net assets of Bellerophon Therapeutics Inc from 2012 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $2.53 Million | -88.28% |
| 2021-12-31 | $21.62 Million | -43.48% |
| 2020-12-31 | $38.25 Million | +965.14% |
| 2019-12-31 | $3.59 Million | -6.87% |
| 2018-12-31 | $3.86 Million | +248.65% |
| 2017-12-31 | $-2.59 Million | -114.42% |
| 2016-12-31 | $17.99 Million | -40.69% |
| 2015-12-31 | $30.34 Million | +32.26% |
| 2014-12-31 | $22.94 Million | +245.75% |
| 2013-12-31 | $-15.74 Million | -41.57% |
| 2012-12-31 | $-11.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bellerophon Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13756100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $96.00K | 3.79% |
| Other Components | $254.52 Million | 10044.04% |
| Total Equity | $2.53 Million | 100.00% |
Bellerophon Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Bellerophon Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The China Fund Inc
F:CHN
|
$146.84K |
|
Portfolioman Pet&Par SustWo KL
CO:PMIPPSW
|
$146.88K |
|
BASLER (BSL.SG)
STU:BSL
|
$146.96K |
|
MEDION
MU:MDN
|
$147.01K |
|
IA Invest FormueFyn Skandi+
CO:IAIFFS
|
$146.69K |
|
VISHAY INTERTECHNOL
BE:VHY
|
$146.52K |
|
EXPRES2ION BIOTECH HLDG
F:5JD
|
$146.33K |
|
QcX Gold Corp
PINK:QCXGF
|
$146.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bellerophon Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 21,619,000 to 2,534,000, a change of -19,085,000 (-88.3%).
- Net loss of 19,831,000 reduced equity.
- New share issuances of 1,437,000 increased equity.
- Other factors decreased equity by 691,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.83 Million | -782.6% |
| Share Issuances | $1.44 Million | +56.71% |
| Other Changes | $-691.00K | -27.27% |
| Total Change | $- | -88.28% |
Book Value vs Market Value Analysis
This analysis compares Bellerophon Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.86 | $0.04 | x |
| 2013-12-31 | $-1.22 | $0.04 | x |
| 2014-12-31 | $1.93 | $0.04 | x |
| 2015-12-31 | $37.09 | $0.04 | x |
| 2016-12-31 | $17.92 | $0.04 | x |
| 2017-12-31 | $-1.00 | $0.04 | x |
| 2018-12-31 | $0.89 | $0.04 | x |
| 2019-12-31 | $0.80 | $0.04 | x |
| 2020-12-31 | $4.91 | $0.04 | x |
| 2021-12-31 | $2.28 | $0.04 | x |
| 2022-12-31 | $0.27 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bellerophon Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -782.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -351.61%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 3.13x
- Recent ROE (-782.60%) is below the historical average (-161.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.12 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-60.42 Million |
| 2014 | -260.16% | 0.00% | 0.00x | 1.46x | $-61.97 Million |
| 2015 | -153.15% | 0.00% | 0.00x | 1.27x | $-49.49 Million |
| 2016 | -132.36% | 0.00% | 0.00x | 1.65x | $-25.61 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-54.56 Million |
| 2018 | 72.98% | 0.00% | 0.00x | 4.76x | $2.43 Million |
| 2019 | -369.45% | 0.00% | 0.00x | 3.65x | $-13.63 Million |
| 2020 | -64.65% | 0.00% | 0.00x | 1.31x | $-28.55 Million |
| 2021 | -82.13% | 0.00% | 0.00x | 1.24x | $-19.92 Million |
| 2022 | -782.60% | -351.61% | 0.71x | 3.13x | $-20.08 Million |
Industry Comparison
This section compares Bellerophon Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bellerophon Therapeutics Inc (BLPH) | $3.72 Million | 0.00% | 0.34x | $146.79K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |